Treatment plans and AD
The top six therapies for AD patients were topical glucocorticoids (32.26%), oral antihistamines (28.66%), moisturizers (19.58%), topical calcineurin inhibitors (TCI) (5.99%), glycyrrhizin (5.82%), and dupilumab (5.8%) (Table 5). There was a significantly higher proportion of severe AD patients who used moisturizer, topical glucocorticoids, TCI, antibiotic ointments, oral antihistamines, oral antibiotics, systemic glucocorticoids, cyclosporine, methotrexate, tripterygium glycosides, glycyrrhizin, thalidomide, NB-UVB phototherapy, dupilumab, gabapentin, antidepressants, and opioids than that of mild and moderate AD patients. Common recommended therapies including TCI (5.99%), dupilumab (5.8%), systematic glucocorticoids (4.05%), cyclosporine (0.82%), methotrexate (0.54%), and NB-UVB (0.76%) have low usage rates in the included population (Table 5).